The human sequence antibody specifically binds to human CTLA-4 or the CTLA-4 on the cell surface of normal human T cell. Herein the antibody is useful for treating human diseases, infections and other conditions using these antibodies.
Figure 1 shows melanoma-specific antibody responses in animals treated with a melanoma vaccine and the anti CTLA-4 antibody 10D1.
Antibody reactivity in pooled plasma samples from treated animals was measured by flow cytometry.
Figure 2 shows the pharmacokinetic profile of the anti CTLA-4 antibody 10D1 during chronic dosing of primates.
Antibody was administered on days 0, 28, 56.84 and 140 and plasma concentrations of 10D1 were analyzed by ELISA. The mean +/-SEM of six treated animals is shown.
Figure 3 shows the pharmacokinetic profile of anti-CTLA-4 antibody 10D1 in prostate cancer patients treated with a single dose of 10D1 at day 0
Plasma concentration (ug/ml) is shown. The mean +/-SEM for 14 treated patients is shown.
Figure 4 Ligand blocking by mAb 10D1. Inhibition of recombinant B7.1 (A) and B7.2 (B) binding to CTLA-4-expressing T cells.
B7-Ig fusion proteins were incubated with huCTLA4 transfectants in the presence of varying concentrations of 10D1 F(ab)2 or isotype control F(ab)2. The mouse anti-human CTLA-4 mAb BNI-3 was also included as a positive control. B7-Ig binding was detected using goat anti-human IgG (Fc-specific)-PE probe. The cell-associated fluorescence was determined by flow cytometry, and percent inhibition of binding was determined.
Davis, T., Lonberg, N., Korman, A., Blanset, S. L., Srinivasan, M., & Graziano, R. F. (2003). Activity and Safety of CTLA-4 Blockade. J Immunol, 171, 6251-6259.
Figure 5 CTLA-4 blockade with mAb 10D1 enhances Ab response to a melanoma vaccine in monkeys
Groups of six cynomolgus monkeys were given s.c. injections of 5106 SKmel-GM cells alone (arrows) or in combination with a bolus i.v. administration of mAb 10D1 (10 mg/kg). Analysis of Ab responses to SKmel-3 cells by flow cytometry (A) or ELISA (B) was determined from plasma samples taken 2 wk after each immunization. The values represent the mean SE from plasma samples, 6/group, tested at a 1/1000 dilution for flow cytometry or 1/200 for ELISA. Statistically significant differences by the Student t test are noted; p= 0.05,p=0.01,p=0.005. C, The individual animal responses by flow cytometry or ELISA (pretreatment values subtracted) at day 97.
Davis, T., Lonberg, N., Korman, A., Blanset, S. L., Srinivasan, M., & Graziano, R. F. (2003). Activity and Safety of CTLA-4 Blockade. J Immunol, 171, 6251-6259.
Figure 6 Ab responses to melanoma and nonmelanoma cell lines in animals treated with melanoma vaccine and mAb 10D1.
Pooled plasma from six cynomolgus monkeys given SKmel-3-GM-CSF vaccine and mAb 10D1 (day 41) was tested for reactivity to a variety of melanoma and nonmelanoma cell lines by flow cytometry (1/1000 dilution).p 0.05human melanoma cell binding vs human nonmelanoma cells.
Davis, T., Lonberg, N., Korman, A., Blanset, S. L., Srinivasan, M., & Graziano, R. F. (2003). Activity and Safety of CTLA-4 Blockade. J Immunol, 171, 6251-6259.
Figure 7 CTLA-4 blockade enhances ADCC activity in response to the melanoma vaccine.
Pooled plasma samples from vaccinated animals with or without 10D1 mAb were taken prior to immunization (Pre) or 2 wk after the second immunization (day 41). The samples were tested for ADCC activity on three melanoma cell lines at a 1/500 dilution.
Davis, T., Lonberg, N., Korman, A., Blanset, S. L., Srinivasan, M., & Graziano, R. F. (2003). Activity and Safety of CTLA-4 Blockade. J Immunol, 171, 6251-6259.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-067 | Anti-Human CTLA4 Recombinant Antibody (Ipilimumab) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
TAB-206 | Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) | WB, IF, IP, Neut, FuncS, ELISA, FC | IgG2 |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G015E | Anti-CTLA4 immunotoxin (scFv)-PE | Cytotoxicity assay, Function study | |
AGTO-G015S | Anti-CTLA4 immunotoxin (scFv)-Sap | Cytotoxicity assay, Function study | |
AGTO-G015M | Anti-CTLA4 immunotoxin (scFv)-Mel | Cytotoxicity assay, Function study |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-195CL | Mouse Anti-CTLA4 Recombinant Antibody (TAB-195CL) | ELISA | Mouse IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-083MZ | Anti-Human CTLA4 Recombinant Antibody (TGN2122.H) | ELISA, FC | Humanized antibody |
TAB-084MZ | Anti-Human CTLA4 Recombinant Antibody (TGN2422.H) | ELISA, FC | Humanized antibody |
TAB-088MZ | Human Anti-CTLA4 Recombinant Antibody (TAB-088MZ) | ELISA | Human IgG |
TAB-091MZ | Human Anti-CTLA4 Recombinant Antibody (TAB-091MZ) | ELISA | Human IgG1 |
TAB-092MZ | Human Anti-CTLA4 Recombinant Antibody (TAB-092MZ) | ELISA | Human IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-085MZ | Anti-Human CTLA4 Recombinant Antibody (TGN2122.C) | ELISA, FC | Chimeric antibody (mouse/human) |
TAB-086MZ | Anti-Human CTLA4 Recombinant Antibody (TGN2422.C) | ELISA, FC | Chimeric antibody (mouse/human) |
TAB-085MZ-S(P) | Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2122.C) | ELISA, FC | Chimeric antibody (mouse/human) |
TAB-086MZ-S(P) | Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2422.C) | ELISA, FC | Chimeric antibody (mouse/human) |
TAB-085MZ-F(E) | Anti-Human CTLA4 Recombinant Antibody Fab Fragment (TGN2122.C) | ELISA, FC | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-087MZ | Mouse Anti-CTLA4 Recombinant Antibody (TAB-087MZ) | ELISA | Mouse IgG |
TAB-089MZ | Mouse Anti-CTLA4 Recombinant Antibody (TAB-089MZ) | ELISA | Mouse IgG1 |
TAB-090MZ | Mouse Anti-CTLA4 Recombinant Antibody (TAB-090MZ) | ELISA | Mouse IgG1 |
TAB-093MZ | Anti-Human CTLA4 Recombinant Antibody (Mu-26B) | ELISA | |
MOB-0317MC | Recombinant Mouse Anti-CTLA4 Antibody | ELISA, FACS |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-567CQ | Mouse Anti-CTLA4 Recombinant Antibody (clone 14D3) | FC, FuncS, Neut, IP, WB | Mouse IgG2a, κ |
NEUT-569CQ | Mouse Anti-CTLA4 Recombinant Antibody (clone AS32) | WB, Neut | Mouse IgG1 |
NEUT-570CQ | Human Anti-CTLA4 Recombinant Antibody (clone YC030) | Neut | Human IgG1, κ |
NEUT-572CQ | Hamster Anti-Ctla4 Recombinant Antibody (clone UC10-4B9) | FC, Block, ELISA, IP | Hamster IgG |
NEUT-573CQ | Rat Anti-Ctla4 Recombinant Antibody (clone 63828) | WB, FC, Neut | Rat IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-568CQ | Mouse Anti-CTLA4 Recombinant Antibody (clone L3D10) | FC, Block | Mouse IgG1, κ |
NEUT-571CQ | Mouse Anti-CTLA4 Recombinant Antibody (clone BN13) | Block, FC | Mouse IgG2a |
NEUT-577CQ | Hamster Anti-Ctla4 Recombinant Antibody (clone MAB0835) | Block, FC | Hamster IgG |
NEUT-578CQ | Hamster Anti-Ctla4 Recombinant Antibody (clone RYNmCTLA-4) | Block | Hamster IgG |
NEUT-579CQ | Hamster Anti-Ctla4 Recombinant Antibody (clone 9H10) | FC, Block | Hamster IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0855 | Hi-Affi™ Rabbit Anti-CTLA4 Recombinant Antibody (clone DS855AB) | WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0157-FY-F(E) | Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0157-FY-F(E)) | Activ | Humanized Fab |
HPAB-N0343-YC-F(E) | Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-N0343-YC-F(E)) | FC, ELISA | Human Fab |
HPAB-0749LY-F(E) | Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0749LY-F(E)) | FuncS, ELISA | Human Fab |
HPAB-0750LY-F(E) | Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0750LY-F(E)) | FuncS, ELISA | Human Fab |
HPAB-0751LY-F(E) | Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0751LY-F(E)) | FuncS, ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0753LY | Human Anti-CTLA4 Recombinant Antibody (HPAB-0753LY) | FuncS, ELISA | Human IgG |
HPAB-0754LY | Human Anti-CTLA4 Recombinant Antibody (HPAB-0754LY) | FuncS, ELISA | Human IgG |
HPAB-0755LY | Human Anti-CTLA4 Recombinant Antibody (HPAB-0755LY) | FuncS, ELISA | Human IgG1 |
HPAB-0756LY | Human Anti-CTLA4 Recombinant Antibody (HPAB-0756LY) | FuncS, ELISA | Human IgG |
HPAB-0757LY | Human Anti-CTLA4 Recombinant Antibody (HPAB-0757LY) | FuncS, ELISA | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-067 | Afuco™ Anti-CTLA4 ADCC Recombinant Antibody (Ipilimumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-206 | Afuco™ Anti-CTLA4 ADCC Recombinant Antibody (Ticilimumab (= Tremelimumab)), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-N0054-YC-S(P) | Human Anti-CTLA4 Recombinant Antibody (clone 4H9-G5-D5-B1); scFv Fragment | ELISA, FC | Human scFv |
HPAB-N0055-YC-S(P) | Human Anti-CTLA4 Recombinant Antibody (clone 9B8-H2-B6-G5); scFv Fragment | ELISA, FC | Human scFv |
HPAB-N0056-YC-S(P) | Human Anti-CTLA4 Recombinant Antibody; scFv Fragment (HPAB-N0056-YC-S(P)) | ELISA, FuncS | Humanized scFv |
HPAB-0270-YJ-S(P) | Human Anti-CTLA4 Recombinant Antibody (clone CBC46YJ); scFv Fragment | ELISA, FC, Block | Human scFv |
HPAB-1097-FY-F(E) | Hamster Anti-Ctla4 Recombinant Antibody (clone FY-002); scFv Fragment | ELISA | Hamster scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-AP860-YC | Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP860-YC) | ELISA, Block | Camel VHH |
HPAB-AP861-YC | Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP861-YC) | ELISA, Block | Camel VHH |
HPAB-AP862-YC | Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP862-YC) | ELISA, Block | Camel VHH |
HPAB-AP863-YC | Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP863-YC) | ELISA, Block | Camel VHH |
HPAB-AP864-YC | Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP864-YC) | ELISA, Block | Camel VHH |
There are currently no Customer reviews or questions for HPAB-0051-YC. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.